HeartFlow’s estimated $150m Series E would make it medtech’s latest unicorn
December 5, 2017
Source: Massdevice
1,919
A reported Series E round for HeartFlow, estimated at $150 million, would value the company at more than $1 billion, vaulting it into unicorn territory.
Redwood City, Calif.-based HeartFlow’s FFRct technology works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing the changes in flow across coronary lesions.
According to a Delaware regulatory filing uncovered by PitchBook and reported by Recode.net, the $25.33 per share valuation would make HeartFlow worth $1.4 billion. HeartFlow’s $99.9 million Series D valued the company at $760 million in May 2016, according to PitchBook.
Earlier this month the company won a new technology ambulatory payment classification from the Centers for Medicare & Medicaid Services.
In late August, HeartFlow said it won positive medical policies for its HeartFlow FFRct fractional flow reserve analysis system from three separate Blue Cross Blue Shield providers.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Disposable Medical Products that Keep Your Medical Facility Clean and Sterile March 31, 2022
- 10 Triumphant Drug Launches Of The Decade August 26, 2021
- Ultrasonic Nebulizer Market Views September 6, 2018
- 4 Best-Selling Digital Thermometers on Drugdu.com in 2018 September 5, 2018
- Don’t Miss These Tips before Your Cardiac Monitor Purchase September 5, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
